RapidPulse Raises $48M Series B to Advance Stroke Thrombectomy Technology

RapidPulse, Inc., a Miami-based neurovascular medical device company spun out of Syntheon, has closed an oversubscribed $48M Series B financing to advance its stroke thrombectomy technology. The round was co-led by Medtronic, TechWald Next S.p.A., and S3 Ventures, with new participation from SBI Investment Company Ltd. and Florida Opportunity Fund.

The company is developing the RapidPulse Aspiration System, a proprietary cyclic aspiration platform intended to remove blood clots during mechanical thrombectomy for acute ischemic stroke. The new capital will support completion of the TURBO IDE study, expanded clinical experience across leading stroke centers, continued catheter platform development, and pursuit of FDA approval if the clinical data supports it.

For the broader medtech market, the financing is another reminder that venture capital has not abandoned hard healthcare problems. It has simply become more selective about backing teams that combine real clinical need, protected technology, regulatory discipline, and enough evidence to keep serious investors engaged.

What Happened

RapidPulse announced the close of its $48M Series B financing on July 16, 2026. The investment was co-led by Medtronic, TechWald Next S.p.A., and S3 Ventures, while SBI Investment Company Ltd. and Florida Opportunity Fund joined the syndicate as new investors. Existing investors Santé Ventures, Syntheon, Hatteras Venture Partners, and Epidarex Capital also continued their support through the new financing.

The company previously raised a $15M Series A in 2021, followed by an additional $10.5M financing in 2022, bringing cumulative funding before this round to approximately $25M. Following the Series B, RapidPulse has raised roughly $73M in disclosed funding. No valuation was disclosed.

RapidPulse is led by CEO Sean McBrayer, alongside COO Heather Harries, VP of Clinical Affairs Cynthia Yang, and VP of Research & Development Derek Deville. The company originated as a Syntheon spinout, reflecting Syntheon's longstanding focus on developing vascular and medical device technologies.

Why This Matters

Stroke treatment is one of the few areas in medicine where every passing minute directly affects long-term patient outcomes. Acute ischemic stroke occurs when blood flow to the brain is blocked by a clot, making rapid restoration of circulation a clinical priority. Mechanical thrombectomy is the procedure used to remove many of those large-vessel clots, so improvements in clot engagement, removal speed, and first-pass success can matter at the bedside.

RapidPulse is developing the RapidPulse Aspiration System, a platform that uses cyclic, or pulsed, aspiration instead of relying solely on continuous vacuum during thrombectomy procedures. The company's approach is intended to improve clot engagement and removal while addressing some of the limitations associated with traditional continuous aspiration systems. That technical distinction may sound incremental, but when treating acute ischemic stroke, small procedural improvements can have meaningful clinical implications.

The company's clinical development is also central to the story. RapidPulse is conducting its TURBO IDE study across the United States and Europe to support its regulatory pathway. As of the Series B announcement, the RapidPulse Aspiration System had not received FDA clearance and was not commercially available.

The Technology Behind RapidPulse

The RapidPulse Aspiration System combines a proprietary aspiration pump with a family of catheters engineered to deliver controlled pulsed aspiration at the catheter tip during thrombectomy procedures. Rather than relying solely on constant suction, the technology is designed to create cyclic vacuum pulses that improve clot interaction during removal. The platform is supported by patented intellectual property, including an issued U.S. patent covering aspects of its aspiration thrombectomy system.

That technical distinction gives RapidPulse a clearer market narrative than another generic medtech funding announcement. The company is not simply arguing that stroke care is important, because that is already well understood. It is making the case that the mechanics of aspiration itself can be improved and that better mechanics may support stronger procedural performance once the clinical evidence is complete.

Why Investors Continue to Back RapidPulse

Oversubscribed financings rarely happen because investors simply like a market category. They happen when multiple factors begin aligning at the same time. RapidPulse brings together an experienced leadership team, proprietary intellectual property, an active clinical program, and participation from both strategic healthcare companies and venture investors with deep medical technology experience.

Medtronic's participation alongside TechWald Next S.p.A. and S3 Ventures brings strategic industry expertise and institutional venture capital into the same round. Continued support from Santé Ventures, Syntheon, Hatteras Venture Partners, and Epidarex Capital suggests the company's existing backers continue to see meaningful progress. For founders watching venture markets closely, the lesson extends beyond the funding amount: capital still rewards companies that demonstrate technical progress, disciplined execution, and a credible regulatory strategy.

What This Signals for the Medtech Market

Medical device investing continues to reward technologies that address significant clinical needs while establishing meaningful technical differentiation. RapidPulse estimates its addressable opportunity against approximately 700,000 strokes occurring annually in the United States. Although commercialization remains dependent on successful clinical outcomes and regulatory approval, investors continue supporting companies working to improve procedural performance in high-impact therapeutic categories.

The Series B financing also reflects a broader pattern across healthcare innovation. Venture firms and strategic investors increasingly favor businesses that combine protected intellectual property, clinical validation, and experienced operators over companies relying primarily on ambitious market narratives. Healthcare has always had less patience for promises than many other sectors because physicians, regulators, hospitals, and investors ultimately ask the same question: does it improve outcomes?

What's Next

RapidPulse plans to use the new capital to complete the TURBO clinical study, expand clinical experience across leading stroke centers, continue development of its proprietary catheter platform, and, contingent on study results, pursue FDA approval for the RapidPulse Aspiration System. That gives the company a clear next chapter, but not a guaranteed ending.

For the startup ecosystem, this financing demonstrates that meaningful healthcare investment continues flowing toward companies combining differentiated technology with disciplined clinical execution. For the neurovascular market, it marks another step toward expanding the tools available to physicians treating one of medicine's most time-sensitive conditions. The market does not need more noise around healthcare innovation. It needs more companies willing to let evidence do the talking.